Ananda Scientific
299 South Main Street
Suite 1300
Salt Lake City
Utah
84111
United States
Tel: 801-676-7745
Website: http://www.anandascientific.com/
Email: admin@anandascientific.com
About Ananda Scientific
ANANDA Scientific, formerly known as ISA Scientific, is answering the call for non-psychoactive and non-abusable, oral cannabinoid products, thus paving the way for substantive improvements in treating debilitating and even life-threatening health conditions afflicting several hundred million people worldwide as well as helping to better health in general.YEAR FOUNDED:
March 2012
LEADERSHIP:
CEO: Hua Bai
CSO: Mark J. Rosenfeld
CTO: Ariel Strahovsky
COO: John J. Abu-Ulba
18 articles about Ananda Scientific
-
ANANDA Scientific Announces First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)
3/28/2023
ANANDA Scientific Inc. today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).
-
University of Nebraska Medical Center and ANANDA Scientific announce First Patient Enrolled in FDA-approved clinical trial for Post-Traumatic Stress Disorder (PTSD)
3/14/2023
The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. today announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia™ ATL5 , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology, for Post-Traumatic Stress Disorder (PTSD).
-
ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)
11/30/2022
ANANDA Scientific Inc today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S.
-
ANANDA Scientific Announces First Patient Enrolled in the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
7/26/2022
ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced the first patient enrolled in the clinical trial evaluating Nantheia™ ATL5 , an investigational drug using cannabidiol (CBD) in ANANDA's proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.
-
Dennis Wong Joins ANANDA Scientific's Board of Directors
7/19/2022
ANANDA Scientific Inc., a research-focused bio-pharmaceutical company, announced that Dennis Wong, President and CEO of Baxco Pharmaceutical Inc, has been appointed to ANANDA Scientific's Board of Directors.
-
Dennis Wong Joins ANANDA Scientific Inc. Board of Directors
7/19/2022
ANANDA Scientific Inc ., a research-focused bio-pharmaceutical company, today announced that Dennis Wong , President and CEO of Baxco Pharmaceutical Inc, has been appointed to A NANDA Scientific's Board of Directors.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
-
ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain
3/8/2022
ANANDA Scientific Inc . today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology.
-
ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
1/4/2022
ANANDA Scientific Inc today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.
-
ANANDA Scientific’s Liquid Structure™ Cannabidiol (CBD) to Be Clinically Evaluated for Opioid Use Disorder
10/19/2021
ANANDA Scientific Inc ., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5 , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial.
-
ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial Evaluating Liquid Structure™ Cannabidiol (CBD) for Treatment of Post-Traumatic Stress Disorder (PTSD)
6/8/2021
ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with Traumatic Brain Injury.
-
ANANDA Scientific and NYU Grossman School of Medicine Announce Second Clinical Trial Utilizing Liquid StructureTM Cannabidiol (CBD) for Evaluating Its Effect on Opioid Sparing in Participants with Chronic Radiculopathic Pain Syndromes
1/28/2021
ANANDA Scientific and NYU Grossman School of Medicine Announce Second Clinical Trial Utilizing Liquid Structure TM Cannabidiol (CBD) for Evaluating Its Effect on Opioid Sparing in Participants with Chronic Radiculopathic Pain Syndromes
-
ANANDA Scientific and NYU Grossman School of Medicine Announce Clinical Trial Utilizing Liquid Structure™ Cannabidiol (CBD) for Treatment of Post-Traumatic Stress Disorder (PTSD)
1/12/2021
ANANDA Scientific Inc., a biotech pharma company, and NYU Grossman School of Medicine today announced a new clinical trial evaluating the efficacy of cannabidiol in ANANDA’s proprietary delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with traumatic brain injury. An Investigational New Drug (IND)
-
ANANDA Scientific Appoints Sohail Zaidi as its New President
9/8/2020
ANANDA Scientific Inc., a biotech pharma company, announced that Sohail Zaidi has been appointed as ANANDA's new President.
-
John Suh Joins ANANDA Scientific's Board of Directors as Executive Director
8/18/2020
ANANDA Scientific Inc., a biotech pharma company, announced that John Suh, previously CEO of LegalZoom, has been appointed to ANANDA's Board of Directors as its new Executive Director.
-
ANANDA Scientific Forms Research Collaboration and License Agreement with Ben-Gurion University for Cannabinoid Products for Topical Applications
11/19/2019
The research will focus on nanotechnology based CBD- products for the treatment of psoriasis and other diseases
-
ISA Scientific Announces Completion Of Corporate Rebrand To Ananda Scientific In Preparation For Leadership In Global CBD Sales
12/21/2016